Oxycodone Market Outlook (2023 to 2033)

According to a recently released report from Future Market Insights, the oxycodone market size is projected to exceed a valuation of US$ 8.92 billion by 2033. This marks a significant increase from its current value of US$ 5.11 billion in 2023. The substantial growth is primarily attributed to the escalating demand for efficient pain management remedies. The sales of oxycodone are likely to consistently rise at a CAGR of 5.7% between 2023 and 2033.

Oxycodone has been a widely prescribed opioid medication, contributing to the growth of the opioid market. However, due to concerns about misuse, addiction, and the opioid crisis, the market has faced increased scrutiny and regulatory interventions in recent years. As a result, the growth of the oxycodone market has been influenced by changing prescribing practices and regulations aimed at curbing opioid abuse.

Oxycodone is a potent opioid analgesic prescribed for moderate to severe pain management. As the population ages and the prevalence of chronic pain conditions such as arthritis and cancer increases, the demand for pain medications like oxycodone can grow.

The development of abuse-deterrent formulations of oxycodone, aimed at reducing the potential for misuse and abuse, has driven market growth. By introducing technologies that make it harder to crush, dissolve, or extract the active ingredient, pharmaceutical companies have sought to address concerns related to opioid abuse while maintaining access to effective pain management options.

The expiration of patents on branded oxycodone formulations has allowed for the entry of generic versions into the market. Generic competition can lead to lower prices, increased market penetration, and expanded access to oxycodone.

While oxycodone has been beneficial for many patients, it has also been associated with misuse, addiction, and overdose. The opioid epidemic, characterized by a surge in opioid-related deaths and addiction rates, has led to increased scrutiny and regulatory interventions. These include prescribing guidelines, monitoring programs, and stricter regulations on the production, distribution, and prescription of opioids.

The ongoing opioid epidemic, fueled partly by the overuse and misuse of prescription opioids, has raised significant public health concerns. The addictive nature of oxycodone and its potential for abuse has led to increased scrutiny and negative perception among the general public. This can result in reduced demand and stricter regulations, affecting the oxycodone market.

Advancements in drug delivery systems, such as extended-release formulations, can provide patients with prolonged pain relief and better convenience. Pharmaceutical companies can explore innovative delivery methods for oxycodone to enhance patient compliance and reduce the risk of misuse.

Attributes Details
Current Year Value (2023) US$ 5.11 billion
Expected Forecast Value (2033) US$ 8.92 billion
Projected CAGR (2023 to 2033) 5.7%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Oxycodone Market Outlook In Comparison to 2023 to 2033 Forecast

FMI's findings reveal that the market experienced a CAGR of 4.8% during the period spanning from 2018 to 2022, reaching a substantial market size of US$ 4.84 billion. Historically, there has been a significant increase in the prescription rates of opioids like oxycodone. Factors such as improved recognition and treatment of pain, aggressive marketing by pharmaceutical companies, and changes in prescribing practices have contributed to the growth of the oxycodone market.

The demand for pain management medication is consistently rising, creating prospects for the expansion of the oxycodone market. The growth trend is expected to continue in response to increasing healthcare spending globally. Considering this, the rising cases of chronic ailments such as rheumatoid arthritis are set to rev up growth opportunities for the market.

Oxycodone is a type of opioid consumed for pain management, anesthesia, and de-addiction. There are typically two forms of oxycodone based on their components: one with a long-acting component and the other with a short-acting component.

They are also known to provide relief after operations, surgeries, and other medical conditions, thereby boosting the demand for oxycodone in the global market. The rising number of chronic diseases such as fibromyalgia, arthritis, lower back pain, and others is accelerating the demand for pain-relieving opioids.

The demand for oxycodone is expected to rise globally as it is prescribed as an analgesic for post-operative pain, HIV, and cancer medication. According to the Centers for Disease Control and Prevention, 239 million surgeries were conducted in 2013. Around 65% of patients experienced moderate to severe post-operative pain, thus bolstering the adoption of oxycodone as an opioid pain management drug.

The global oxycodone market is expected to face certain restraints due to increased opioid abuse and mortality. In 2017, opioids were responsible for 66% of drug overdose deaths in the United States alone. However, in the coming years, the market is likely to benefit from government support and the development of new drugs that do not cause addiction.

The opioid crisis has prompted a shift in focus toward non-opioid and alternative pain management strategies. There is increasing interest in developing non-addictive pain medications or non-pharmacological interventions. Pharmaceutical companies can explore research and development opportunities in this area while ensuring patient safety and efficacy.

How does The Increasing Prevalence of Chronic Diseases Affect the Oxycodone Market?

The growth of the oxycodone market is being shaped by the rising number of chronic disorders. It is commonly prescribed for post-surgery pain management. One significant driving factor is the increasing prevalence of Parkinson's syndrome.

According to BlueCross BlueShield, the prevalence of Parkinson's disease is gradually rising among young adults. Additionally, the Parkinson's Foundation reports that about 1 million people in the United States are living with the condition.

Patients with Parkinson's disease experiencing severe pain are sometimes prescribed long-acting oxycodone treatment, which has shown clinical improvements compared to a placebo.

Oxycodone also benefits patients with rheumatic conditions and cancer, as it helps improve pain management. Moreover, it is primarily used as a pain reliever after operations and surgeries, gaining momentum from these advancements.

Considering these factors, the increasing application of oxycodone in pain management indicates potential for market expansion in the near future. Restrains Give Way to New Development in the Global Oxycodone Market

Opioids are primarily used for pain relief; however, their addictive nature is a significant concern. While they offer cost-effective solutions for patients suffering from pain caused by various ailments, their addictive properties make them susceptible to abuse.

The consumption of opioids can lead to various side effects, including euphoria, slowed breathing, nausea, constipation, drowsiness, and confusion. To address the issue of addiction associated with opioids, there are ongoing research and development activities, supported by government reimbursement, aimed at developing oxycodone drugs that can help prevent addiction. These efforts are expected to create new opportunities for market growth during the forecast period.

The market is likely to experience growth due to the increase in new drug applications and the presence of pipeline products in pharmaceutical companies.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-wise Analysis

Countries 2022 Value Share in Global Market
United States 91.3%
Japan 23.7%

Is the United States Poised to Remain a Key Market for Oxycodone?

The United States oxycodone market has witnessed significant growth in recent years, driven by factors such as

  • the rising prevalence of chronic pain
  • increasing demand for pain management drugs
  • the availability of advanced formulations

The United States is projected to maintain its position as a leader in the global market due to its substantial purchasing power derived from its large economy. According to the National Health Accounts by Centers for Medicare & Medicaid Services (CMS), healthcare spending in the country experienced a growth rate of 4.6% in 2019.

With healthcare expenditure expected to continue rising, there is likely to be a corresponding increase in the demand for oxycodone in the United States. This demand is projected to be driven by the escalating prevalence of chronic diseases in the country.

In response to the opioid crisis, the United States government has implemented stricter regulations and policies to control the prescribing and dispensing opioids, including oxycodone. These measures aim to curb misuse, abuse, and diversion of these drugs while ensuring access for patients in genuine need.

The United States has been grappling with an opioid epidemic, and oxycodone has played a significant role in the crisis. The misuse and abuse of opioids, including oxycodone, have led to a surge in addiction, overdoses, and fatalities. As a result, there has been a heightened focus on monitoring, prevention, and treatment programs nationwide.

The market in the United States is further strengthened by the presence of key players such as Purdue Pharma, Pfizer Inc., Janssen Pharmaceuticals Inc., Endo Pharmaceuticals, and others. Consequently, the oxycodone market in the United States is anticipated to exhibit promising growth in the forthcoming years.

Why is Oxycodone becoming a Vital Treatment Option for Cancer Pain in Japan?

Japan has one of the world's largest aging populations. Older adults are more likely to suffer from chronic pain conditions like cancer-related pain and osteoarthritis. The rise in the elderly population has contributed to the increased demand for pain management medications, including oxycodone.

There has been a shift in attitudes toward pain management in Japan. Traditionally, there was a reluctance to use opioids due to concerns about addiction and side effects. However, there is now a growing acceptance of opioids as a necessary treatment option for patients with severe pain, which has positively impacted the Japan oxycodone market.

Cancer rates in Japan have been steadily rising, leading to an increased demand for pain medications. Oxycodone is often prescribed to cancer patients experiencing severe pain, and this trend has contributed to the market growth.

The government has implemented strict regulations and monitoring systems to prevent misuse and diversion of opioids. The Act on the Rational Use and Proper Dispensing of Narcotics and Psychotropics ensure that opioids, including oxycodone, are prescribed and dispensed under close supervision.

Countries Value CAGR (2023 to 2033)
United Kingdom 5.5%
China 5.6%
India 4.1%

What are the Factors Driving Oxycodone Demand in the United Kingdom?

A shift toward alternative pain management strategies influences the United Kingdom oxycodone market. The country has witnessed a rise in the prescription rates of oxycodone over the past decade. This phenomenon can be ascribed to a range of factors, including

  • an aging population
  • increasing prevalence of chronic pain conditions
  • the healthcare system's approach to pain management

According to the Office of National Statistics in the United Kingdom, healthcare expenditure in 2018 amounted to about US$ 230 billion, accounting for 10% of the country's total expenditure. Government financing of healthcare experienced a growth rate of 2.0%.

The increase in healthcare expenditure in the United Kingdom can be attributed to the rising prevalence of chronic diseases. Additionally, improved access to information has led to increased awareness among individuals about various medical conditions, resulting in a greater willingness to invest in advanced healthcare.

The misuse and addiction to oxycodone have become a key concern in the country. The rise in misuse has led to increased hospital admissions, overdose cases, and fatalities. The government and healthcare organizations have been taking measures to address this issue.

The government has taken several steps to address the opioid crisis, including the establishment of the Opioid Painkiller Addiction Working Group. This group aims to develop prevention, treatment, and recovery support strategies for individuals affected by opioid addiction.

These factors are expected to have a positive impact on the United Kingdom market, creating a favorable environment for the growth of oxycodone sales.

Is China Oxycodone Market Riding the Wave of Increasing Chronic Pain Cases?

The rising prevalence of chronic pain conditions, such as cancer, arthritis, and neuropathy, has fueled the demand for effective pain management solutions in China, including oxycodone. The aging population contributes to the growing burden of chronic pain, driving the market growth. Additionally, the improving standard of living and increasing awareness about pain management have contributed to the market growth.

There has been an increased awareness and acceptance of opioid analgesics, including oxycodone, among healthcare professionals and patients in China. This shift is attributed to improved education about pain management, the effectiveness of opioids, and the availability of newer formulations.

China has witnessed significant changes in its regulatory environment concerning opioid medications. The government has implemented stricter controls and monitoring systems to prevent misuse, diversion, and addiction to opioids, including oxycodone. These measures aim to strike a balance between patient access to pain relief and preventing substance abuse.

The market in China has witnessed consolidation, with a few key pharmaceutical companies dominating the market. These companies have focused on developing innovative formulations, enhancing their distribution networks, and expanding their market reach.

Is Palliative Care Driving the Demand for Oxycodone in India?

The India oxycodone market has experienced significant growth in recent years, driven by

  • increasing incidences of chronic pain
  • rising geriatric population
  • growing awareness about pain management

Chronic pain conditions, such as cancer-related pain, osteoarthritis, and post-operative pain, have risen in India. This trend has fueled the demand for oxycodone as an effective pain management option.

According to the Indian Council of Medical Research (ICMR) and India's National Centre for Disease Informatics and Research, the number of cancer cases in males alone is projected to increase from approximately 679,421 to an estimated 763,575 by 2025.

The escalating number of cancer cases is expected to contribute to the growing demand for effective pain management solutions. This trend is expected to positively impact the growth of the oxycodone market in India. Additionally, the expansion of the healthcare sector to meet the increasing healthcare requirements of the population is likely to create further opportunities for growth in the country.

India has a rapidly aging population, resulting in a higher incidence of age-related diseases and chronic pain conditions. Older people often require long-term pain management, leading to an increased demand for oxycodone.

The Narcotic Drugs and Psychotropic Substances Act 1985 regulates the sale, distribution, and use of oxycodone in India. The government has implemented stringent regulations to prevent the misuse and diversion of opioids while ensuring access to pain management for legitimate patients.

The Indian government has recognized the importance of palliative care and has taken steps to improve access to pain management services. This focus on palliative care has led to increased use of opioids like oxycodone for providing relief to patients with chronic pain.

Category-wise Insights

Segment Forecasted CAGR (2023 to 2033)
Long Acting Oxycodone 70.31%
Pain Management 78.68%
Retail Pharmacies 75.8%

Why is Long Acting Oxycodone Gaining Popularity?

Long acting oxycodone is anticipated to experience greater sales compared to short-acting oxycodone due to several advantages it offers. One key advantage is the reduced dosing frequency, providing extended pain relief over longer periods. This extended treatment is especially beneficial for patients with persistent pain levels and for those who have not found satisfactory pain relief from non-opioid treatments.

Long acting oxycodone is designed to provide around-the-clock pain relief, typically lasting for 12 to 24 hours. This extended duration of action helps maintain a more stable blood concentration of the medication, leading to better pain control and reduced fluctuations in pain intensity.

The extended-release formulation allows for individualized dosing, with different strengths available to match patients' specific needs. Healthcare providers can select an appropriate dosage based on the severity of the pain and the patient's response to previous treatments.

Long-acting oxycodone is expected to witness an increase in demand due to its ability to maintain consistent and prolonged levels of the drug in the bloodstream, resulting in reduced peak and trough fluctuations. Furthermore, the improved dosing schedule of long-acting oxycodone allows patients to have a more structured medication routine, minimizing the need to constantly watch the clock between doses.

Is the Dominance of Pain Management Applications Shaping the Oxycodone Market?

Oxycodone is a potent opioid analgesic commonly prescribed for managing moderate to severe pain. There is a significant global burden of pain-related conditions such as postoperative, cancer, and chronic non-cancer pain. The demand for effective pain management solutions drives the use of oxycodone in the pain management application segment.

Oxycodone is known for its strong analgesic properties. It acts on the central nervous system to alleviate pain by binding to opioid receptors in the brain and spinal cord. This makes it effective in managing various types of pain, including acute and chronic pain. The drug's potency and effectiveness contribute to its dominance in the pain management segment.

In severe pain that is not adequately controlled by other analgesics, oxycodone may be prescribed as a last resort. Alternatives to oxycodone, such as non-opioid analgesics or weaker opioids, may not relieve pain in certain situations. Consequently, oxycodone remains a preferred choice for pain management in cases where other options are inadequate.

What Factors Contribute to the Higher Demand for Oxycodone in Retail Pharmacies?

Retail pharmacies are widely available and easily accessible to the general public. Patients can visit these pharmacies to obtain prescribed medications, including oxycodone. The convenience and proximity of retail pharmacies make them a popular choice for patients seeking pain relief medications.

Retail pharmacies are subject to strict regulations and oversight by government agencies, such as the Drug Enforcement Administration (DEA) in the United States. These regulations ensure proper handling, storage, and dispensing of controlled substances like oxycodone, making retail pharmacies a trusted source for patients and healthcare providers.

Retail pharmacies often provide additional services, such as patient counseling and education about medication use, potential side effects, and precautions. This can help promote responsible and safe usage of oxycodone, reducing the risks associated with its misuse or abuse.

Retail pharmacies have well-established supply chain management systems that allow them to maintain inventory and restock medications efficiently. This ensures a steady and reliable supply of oxycodone to meet the demands of patients.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Competitive Landscape

The global oxycodone market is highly fragmented as there are numerous notable players operating in the market. Key strategies that market players are using to gain an edge include:

  • Investing in research and development: Market players are investing heavily in research and development to develop new and improved oxycodone products. This includes developing new formulations of oxycodone that are more difficult to abuse and new indications for oxycodone.
  • Expanding product portfolio: Market players are also expanding their product portfolio by acquiring smaller companies or developing new products in-house. This allows them to offer a wider range of oxycodone products to meet the needs of different patients.
  • Focusing on key markets: Market players are focusing their efforts on key markets, such as the United States and Europe. These markets are home to many potential patients and have high healthcare spending.
  • Building relationships with key stakeholders: Market players are building relationships with key stakeholders, such as healthcare professionals, patients, and policymakers. This helps them to gain a better understanding of the needs of these stakeholders and to develop products and services that meet these needs.

In addition to the strategies mentioned above, oxycodone market players are also focusing on developing new delivery methods for oxycodone. For example, certain companies are developing oxycodone patches that can be applied to the skin, while others are developing oxycodone nasal sprays. These new delivery methods offer several advantages over traditional oral formulations of oxycodone, such as faster onset of action, improved pain relief, and reduced risk of abuse.

Recent Developments by Key Oxycodone Market Players:

  • Teva Pharmaceutical Industries Ltd. got FDA approval for VANTRELATM ER extended-release tablets that were formulated with Teva’s proprietary abuse deterrence technology for managing daily severe pain. The product’s approval was supported by a clinical program to evaluate efficacy, safety, and abuse potential of VANTRELA ER.
  • Purdue Pharma signed an agreement with United States Department of Justice to deliver more than US$ 10 billion in value opioid crisis to communities and claimants.
  • Mylan and Pfizer collaborated under combination of Mylan and Upjohn to form Viatris. The company is expected to flourish into a sustainable healthcare journey by expanding medicine access and meeting patient needs.

How can Oxycodone Market Players Grow Their Businesses?

  • Expand market reach through strategic partnerships with healthcare providers, hospitals, and pharmacies.
  • Invest in research and development to enhance the formulation and delivery of oxycodone products, focusing on improved efficacy, safety, and convenience.
  • Develop and promote extended-release formulations to relieve long-lasting pain and reduce dosing frequency.
  • Conduct clinical trials to gather robust evidence of the effectiveness and safety of oxycodone, positioning it as a trusted and preferred choice among healthcare professionals.
  • Invest in marketing and educational campaigns targeted at healthcare professionals to increase awareness and understanding of oxycodone's benefits, appropriate usage, and potential risks.
  • Strengthen relationships with regulatory authorities to ensure compliance with evolving regulations and expedite the approval process for new oxycodone products.
  • Implement comprehensive pharmacovigilance programs to monitor and report adverse events associated with oxycodone, demonstrating a commitment to patient safety.
  • Explore international markets by obtaining necessary regulatory approvals and adapting marketing strategies to local cultural and regulatory landscapes.
  • Provide support services to patients, such as educational materials, adherence programs, and access to patient assistance programs, to enhance patient outcomes and satisfaction.
  • Collaborate with healthcare providers and organizations to develop and implement pain management guidelines prioritizing the appropriate and responsible use of oxycodone.
  • Invest in data analytics and technology to gain insights into prescribing patterns, patient demographics, and market trends, enabling targeted marketing strategies and informed decision-making.

Leading Oxycodone Manufacturers as Profiled by FMI include:

  • Teva Pharmaceutical Industries Ltd.
  • Purdue Pharma L.P
  • Daiichi Sankyo
  • Acorda Therapeutics
  • Teikoku Pharma USA, Inc.
  • Mylan N.V
  • Endo Pharmaceuticals Inc.
  • Janssen Pharmaceuticals, Inc.

Key Segments Covered in Oxycodone Market Study

By Oxycodone Type:

  • Long-acting oxycodone
  • Short-acting oxycodone

By Application:

  • Pain Management
  • De-addiction

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the Expected Net Worth of Oxycodone Market?

The net worth of the oxycodone market is expected to be US$ 8.92 billion by 2033.

What is the Calculated CAGR for the Market Forecast?

The market is calculated to expand at a CAGR of 5.7% through 2033.

How Did the Market Perform in the Historical Period?

The market expanded at a CAGR of 5.7% from 2018 to 2022.

Which Factors are Shaping the Market’s Landscape?

High occurrence of chronic pain conditions and increasing focus on the awareness programs.

Who are the Leading Manufacturers in the Oxycodone Market?

The leading manufacturers are Purdue Pharma L.P, Daiichi Sankyo, and Acorda Therapeutics.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Long-acting oxycodone

        5.3.2. Short-acting oxycodone

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application, 2023 to 2033

        6.3.1. Pain Management

        6.3.2. De-addiction

    6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Application

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Application

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Application

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Application

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Type

        11.2.3. By Application

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Application

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Type

        12.2.3. By Application

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Application

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Type

        13.2.3. By Application

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Application

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Type

        14.2.3. By Application

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Application

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Type

        15.2.3. By Application

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Type

        15.3.3. By Application

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Type

            16.1.2.2. By Application

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Type

            16.2.2.2. By Application

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Type

            16.3.2.2. By Application

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Type

            16.4.2.2. By Application

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Type

            16.5.2.2. By Application

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Type

            16.6.2.2. By Application

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Type

            16.7.2.2. By Application

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Type

            16.8.2.2. By Application

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Type

            16.9.2.2. By Application

            16.9.2.3. By Distribution Channel

    16.10. China

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Type

            16.10.2.2. By Application

            16.10.2.3. By Distribution Channel

    16.11. Japan

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Type

            16.11.2.2. By Application

            16.11.2.3. By Distribution Channel

    16.12. South Korea

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Type

            16.12.2.2. By Application

            16.12.2.3. By Distribution Channel

    16.13. Singapore

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Type

            16.13.2.2. By Application

            16.13.2.3. By Distribution Channel

    16.14. Thailand

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Type

            16.14.2.2. By Application

            16.14.2.3. By Distribution Channel

    16.15. Indonesia

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Type

            16.15.2.2. By Application

            16.15.2.3. By Distribution Channel

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Type

            16.16.2.2. By Application

            16.16.2.3. By Distribution Channel

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Type

            16.17.2.2. By Application

            16.17.2.3. By Distribution Channel

    16.18. GCC Countries

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Type

            16.18.2.2. By Application

            16.18.2.3. By Distribution Channel

    16.19. South Africa

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Type

            16.19.2.2. By Application

            16.19.2.3. By Distribution Channel

    16.20. Israel

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Type

            16.20.2.2. By Application

            16.20.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Type

        17.3.3. By Application

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Teva Pharmaceutical Industries Ltd.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

                18.1.1.5.2. Product Strategy

                18.1.1.5.3. Channel Strategy

        18.1.2. Purdue Pharma L.P

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

                18.1.2.5.2. Product Strategy

                18.1.2.5.3. Channel Strategy

        18.1.3. Daiichi Sankyo

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

                18.1.3.5.2. Product Strategy

                18.1.3.5.3. Channel Strategy

        18.1.4. Acorda Therapeutics

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

                18.1.4.5.2. Product Strategy

                18.1.4.5.3. Channel Strategy

        18.1.5. Teikoku Pharma USA, Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

                18.1.5.5.2. Product Strategy

                18.1.5.5.3. Channel Strategy

        18.1.6. Mylan N.V

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

                18.1.6.5.2. Product Strategy

                18.1.6.5.3. Channel Strategy

        18.1.7. Endo Pharmaceuticals Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

                18.1.7.5.2. Product Strategy

                18.1.7.5.3. Channel Strategy

        18.1.8. Janssen Pharmaceuticals, Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

                18.1.8.5.2. Product Strategy

                18.1.8.5.3. Channel Strategy

        18.1.9. Johnson & Johnson

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

                18.1.9.5.2. Product Strategy

                18.1.9.5.3. Channel Strategy

        18.1.10. Pfizer Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

                18.1.10.5.2. Product Strategy

                18.1.10.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Pain Management Devices Market

October 2022

REP-GB-14306

315 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Oxycodone Market

Schedule a Call